RAINBOW
Rainbow Childrens Med
Each stock's 10,000-path forecast, rendered as light.
Rainbow Childrens Med (RAINBOW) Stock Analysis & Case Study
Is RAINBOW a good buy? The data-driven verdict.
Rainbow Childrens Med (RAINBOW) trades at ₹1,447,on the numbers it mixed signals, a Downstox Snapshot Score of 45/100.
On the numbers, Rainbow Childrens Med (RAINBOW) mixed signals, a Downstox Snapshot Score of 45/100, weighing expensive at 52.4× earnings, ROE of 17.9%, a 55% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
RAINBOW fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is RAINBOW overvalued? RAINBOW P/E vs its sector
RAINBOW's P/E of 52.4× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.24% dividend yield is below the peer median of 1.65%.
RAINBOW share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of RAINBOW history (7%/yr drift, 29%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| RAINBOW 2027 | ₹1,053 | ₹1,523 | ₹2,198 | +4% |
| RAINBOW 2028 | ₹937 | ₹1,572 | ₹2,642 | +7% |
| RAINBOW 2029 | ₹857 | ₹1,621 | ₹3,074 | +10% |
| RAINBOW 2030 | ₹804 | ₹1,668 | ₹3,556 | +13% |
| RAINBOW 2031 | ₹757 | ₹1,733 | ₹3,929 | +18% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability RAINBOW goes up, or doubles?
The bull case for RAINBOW
- A healthy 17.9% return on equity.
- Strong ROCE (18.2%) shows the core business earns well above its cost of capital.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹3,074.
The bear case & risks
- A rich 52.4× P/E leaves a thin margin of safety if growth slows.
- A steep 8.9× price-to-book means most of the value is intangible/expectations, not assets on the books.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹857.
RAINBOW volatility & expected range, how bumpy is the ride?
Over the last 2.0 years RAINBOW compounded at 7%/year with annualized volatility of 29%. That volatility implies a 1-year 80% range of ₹1,053–₹2,198, the honest backbone behind any single price target.
RAINBOW price forecast, the full 60-month probability fan
RAINBOW price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds RAINBOW hits common targets within the simulated horizon?
Full multi-horizon detail on the RAINBOW price target & forecast page.
RAINBOW Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. RAINBOW scores 4/9,mixed financial health.
RAINBOW MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy RAINBOW with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 28.4% | 3.5× |
| ZerodhaCHEAPEST | 28.4% | 3.5× |
| DhanCHEAPEST | 28.4% | 3.5× |
Compare every broker on the RAINBOW MTF page.
RAINBOW vs peers,sector comparison
About Rainbow Childrens Med: sector, index & market-cap context
Rainbow Childrens Med (RAINBOW) is a small-cap NSE-listed company, and a constituent of the Nifty 200 index group, with a market capitalisation of ₹14,632 Cr. See more Nifty 200 stocks.
How the RAINBOW Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Rainbow Childrens Med's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
RAINBOW analysis, FAQs
Is Rainbow Childrens Med (RAINBOW) a good buy?
On the numbers, Rainbow Childrens Med (RAINBOW) mixed signals, a Downstox Snapshot Score of 45/100, weighing expensive at 52.4× earnings, ROE of 17.9%, a 55% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is RAINBOW overvalued or undervalued?
RAINBOW trades at 52.4× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the RAINBOW share price target for 2031?
RAINBOW's probability-weighted 2031 median target is ₹1,733, with an 80% range of ₹757–₹3,929 (10,000-path Monte-Carlo).
What is the probability RAINBOW doubles in 5 years?
The modelled probability of RAINBOW reaching ₹2,942 (2×) within 5 years is 21%.
What is the bull case for RAINBOW?
A healthy 17.9% return on equity. Strong ROCE (18.2%) shows the core business earns well above its cost of capital.
What are the risks in RAINBOW?
A rich 52.4× P/E leaves a thin margin of safety if growth slows. A steep 8.9× price-to-book means most of the value is intangible/expectations, not assets on the books.